Safety of Novel Oral Anticoagulants Compared With Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation
- 16 December 2014
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 49 (3) , 278-284
Abstract
Background: The novel oral anticoagulants (NOACs) are used for stroke prevention in atrial fibrillation (AF), but their safety and efficacy in the periablation period are not well established. Additionally, no standard procedure for managing periprocedural and intraprocedural anticoagulation has been established. Objective: To evaluate the frequency of hemorrhagic and thrombotic events as well as periprocedural management strategies of NOACs compared with warfarin as anticoagulation therapy for AF ablation. Methods: This was a retrospective cohort study from a prospective AF ablation registry maintained at a large, academic medical center. Results: A total of 374 cases (173 warfarin, 123 dabigatran, 61 rivaroxaban, and 17 apixaban) were included in the analysis. The overall hemorrhagic/thrombotic event rate was 14.2 % (major hemorrhage 2.7%, minor hemorrhage 11.2%, thrombotic stroke 0.5%). The frequency of minor hemorrhage was significantly higher with warfarin compared with dabigatran (15% vs 5.7%, P = 0.012). The average heparin dose required to reach the goal activated clotting time (ACT) was 5600 units for warfarin, 12 900 units for dabigatran (P < 0.001), 15 100 units for rivaroxaban (P < 0.001), and 14 700 units for apixaban (P < 0.001). The average time in minutes to reach the goal ACT was significantly longer, compared with warfarin, for dabigatran (57 vs 28, P < 0.001), rivaroxaban (63 vs 28, P < 0.001), and apixaban (72 vs 28, P < 0.001). Conclusions: Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation. Patients anticoagulated with NOACs required larger doses of heparin and took longer to reach the goal ACT compared with patients anticoagulated with warfarin.Keywords
This publication has 20 references indexed in Scilit:
- Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2013
- Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillationEP Europace, 2013
- Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stayJournal of Interventional Cardiac Electrophysiology, 2013
- Dabigatran versus Warfarin Therapy for Uninterrupted Oral Anticoagulation During Atrial Fibrillation AblationJournal of Cardiovascular Electrophysiology, 2013
- Usefulness of Dabigatran Etexilate as Periprocedural Anticoagulation Therapy for Atrial Fibrillation AblationClinical Drug Investigation, 2013
- Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillationHeart Rhythm, 2013
- A comparison of bleeding complications post-ablation between warfarin and dabigatranJournal of Interventional Cardiac Electrophysiology, 2012
- Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial FibrillationJACC, 2012
- Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial FibrillationCirculation Journal, 2012
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009